published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or ventilationdetailed resultsNCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66] 3.60[0.13; 102.66]NCT04310228-FAVI (Zhao), 202010%12NAnot evaluable radiologic improvement (14-day)detailed resultsNCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63] 0.32[0.06; 1.63]NCT04310228-FAVI (Zhao), 202010%NAnot evaluable adverse eventsdetailed resultsNCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80] 0.60[0.05; 6.80]NCT04310228-FAVI (Zhao), 202010%12NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-19 10:47 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 557,635,1236,553,628,646,645,607,395 - roots T: 290